cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.

Systemic therapy of metastatic melanoma.

Radiation therapy for advanced and metastatic melanoma.

Systemic therapy of non-resectable metastatic melanoma.

Prospects for gene therapy and lymphokine therapy for metastatic melanoma.

Interleukin-2 therapy for metastatic uveal melanoma.

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma.

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma.

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.

Evaluation of anti-metastatic potential of Cisplatin polymeric nanocarriers on B16F10 melanoma cells.

Metastatic melanoma and immunotherapy.

Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma.

Myositis and metastatic melanoma.

Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum.

Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma.

Radiofrequency ablation in metastatic melanoma.

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis.

Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.

Amelanotic metastatic cutaneous melanoma.

Cobimetinib for metastatic melanoma.

GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.

Metastatic tapioca iris melanoma.

Suggest Documents

Systemic therapy of metastatic melanoma.

Radiation therapy for advanced and metastatic melanoma.

Systemic therapy of non-resectable metastatic melanoma.

Prospects for gene therapy and lymphokine therapy for metastatic melanoma.

Interleukin-2 therapy for metastatic uveal melanoma.

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma.

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma.

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.

Evaluation of anti-metastatic potential of Cisplatin polymeric nanocarriers on B16F10 melanoma cells.

Metastatic melanoma and immunotherapy.

Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma.

Myositis and metastatic melanoma.

Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum.

Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma.

Radiofrequency ablation in metastatic melanoma.

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis.

Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.

Amelanotic metastatic cutaneous melanoma.

Cobimetinib for metastatic melanoma.

GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.

Metastatic tapioca iris melanoma.

cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.

Recommend Documents

Follow Us